REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
13 April 2017
Alliance Provides Wider Access to Oncology Biospecimens to Accelerate Discovery and Translational Studies
Location: REPROCELL USA Inc. (Beltsville, MD)
Business Unit: REPROCELL Discovery
Date: April 13, 2017
Announcement (Marketwired) — REPROCELL and Fox Chase Cancer Center today announced a strategic alliance aimed at accelerating oncology discovery and translational studies. Through this alliance, REPROCELL will augment its Global Repository of bio- specimens with samples from the Fox Chase Cancer Center, ensuring that researchers have access to the widest array of clinical-grade biospecimens.
“REPROCELL’s alliance with Fox Chase ensures that the oncology research and develop- ment market has access to a premium source of clinically annotated tissue specimens,” said Rama Modali, CEO of REPROCELL USA. “The scope and sustainability of specimens collected by Fox Chase is as unique as it is impressive, covering nearly every major solid tumor type.”
Today, industry and academia need access to clinical data and biospecimens to accelerate discovery and translational studies. Internationally renowned for cancer research and treatment, Fox Chase Cancer Center also serves as the center of a comprehensive patient care network covering the densely populated three-state region surrounding
Philadelphia. As a result, tissue and blood specimens collected for the repository can trace each anonymized patient’s pathway from pre-diagnosis to treatment and through long- term follow-up care. Fox Chase specimens collected at each stage are supported by annotations that include medical histories, detailed records of treatment protocols as well as outcomes.
“Our biosamples have tremendous clinical value, and getting them into the hands of as many cancer researchers as possible is a priority for us,” said Richard I. Fisher, MD, president & CEO of Fox Chase Cancer Center. “We know that making our biosamples avail- able to the wider scientific community will accelerate the pace of cancer research.”
As a leading provider of biomaterials, REPROCELL is deeply engaged with cancer research being conducted by pharma, biotech and leading academic research institutions world-wide.
About Fox Chase Cancer Center
The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nurs- ing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Headquartered in Yokohama (Japan), REPROCELL is an integrated research and medical company. Serving the global market, the REPROCELL Discovery business unit is focused on providing drug discovery services and products including human tissues and cutting-edge iPS stem cell technologies. Leveraging this history and strength, the REPROCELL Medical business unit (formed 2017) is pioneering stem cell-based applications for regenerative medicine therapies and human diagnostics. REPROCELL (https://reprocell.com) is a public company traded on the JASDAQ market. For more information on this press release contact your regional REPROCELL office (phone numbers and e-mails provided on the website listed above).